中國生物科技服務(08037.HK)一季度盈轉虧至1537.5萬港元
格隆匯5月11日丨中國生物科技服務(08037.HK)公佈,截至2023年3月31日止三個月,公司收益為1.31億港元,同比減少66.01%;公司股東應占期內虧損為1537.5萬港元,去年同期則盈利為3493.8萬港元;基本每股虧損為0.016港仙。
公吿顯示,於2022年爆發COVID-19第五波後引進新的抗病毒口服藥物以及二價疫苗,標誌着抗擊疫症大流行之重大轉捩點。COVID-19疫情快速改變以及香港政府迅速放寬所採取之COVID-19相關檢疫防控措施,對集團COVID-19核酸檢測服務之需求產生負面影響。COVID-19威脅消退亦影響到2023年第一季度期間內快速抗原測試試劑盒之銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.